

Clinical Profiles and Prognosis of Patients with Distinct

Journal of Rheumatology

44, 1051-1057

DOI: 10.3899/jrheum.161480

Citation Report

#	ARTICLE	IF	CITATIONS
1	The emergence of sarcopenia as an important entity in older people. <i>Clinical Medicine</i> , 2017, 17, 590-591.	0.8	0
2	Antisynthetase syndrome. <i>Clinical Medicine</i> , 2017, 17, 591.2-591.	0.8	0
3	The hyperacute neurology team. <i>Clinical Medicine</i> , 2017, 17, 591.4-592.	0.8	0
4	Autoantibodies in myositis. <i>Nature Reviews Rheumatology</i> , 2018, 14, 290-302.	3.5	248
5	New Myositis Classification Criteria—What We Have Learned Since Bohan and Peter. <i>Current Rheumatology Reports</i> , 2018, 20, 18.	2.1	65
6	Palmar and plantar erythema, pulmonary fibrosis and the anti-synthetase syndrome. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2018, 111, 329-330.	0.2	1
7	Clinical features and outcome of patients with acute respiratory failure revealing anti-synthetase or anti-MDA-5 dermatopulmonary syndrome: a French multicenter retrospective study. <i>Annals of Intensive Care</i> , 2018, 8, 87.	2.2	60
8	Myositis an evolving spectrum of disease. <i>Immunological Medicine</i> , 2018, 41, 46-54.	1.4	14
9	The clinico-serological spectrum of overlap myositis. <i>Current Opinion in Rheumatology</i> , 2018, 30, 637-643.	2.0	20
10	Predictive Factors for the Long-Term Deterioration of Pulmonary Function in Interstitial Lung Disease Associated with Anti-Aminoacyl-tRNA Synthetase Antibodies. <i>Respiration</i> , 2018, 96, 210-221.	1.2	32
11	Interstitial Lung Disease in Polymyositis and Dermatomyositis. <i>Clinics in Chest Medicine</i> , 2019, 40, 561-572.	0.8	72
12	Clinical characteristics of dermatomyositis patients with isolated anti-Ro-52 antibody associated rapid progressive interstitial lung disease: Data from the largest single Chinese center. <i>Respiratory Medicine</i> , 2019, 155, 127-132.	1.3	17
14	Presentations and outcomes of interstitial lung disease and the anti-Ro52 autoantibody. <i>Respiratory Research</i> , 2019, 20, 256.	1.4	23
15	Jo1-antisynthetase syndrome and severe interstitial lung disease with organising pneumonia on histopathology with favourable outcome on early combined treatment with corticosteroids, mycophenolate mofetil and rituximab. <i>BMJ Case Reports</i> , 2019, 12, e231006.	0.2	13
16	Disease Specific Autoantibodies in Idiopathic Inflammatory Myopathies. <i>Frontiers in Neurology</i> , 2019, 10, 438.	1.1	32
17	Clinical Features and Cytokine Profile in Myositis Patients with Anti-EJ Autoantibodies Detected by a Novel Immunoprecipitation Assay. <i>BioMed Research International</i> , 2019, 2019, 1-9.	0.9	4
18	Prognostic factors of interstitial lung disease progression at sequential HRCT in anti-synthetase syndrome. <i>European Radiology</i> , 2019, 29, 5349-5357.	2.3	33
19	Biomarkers in Adult Dermatomyositis: Tools to Help the Diagnosis and Predict the Clinical Outcome. <i>Journal of Immunology Research</i> , 2019, 2019, 1-15.	0.9	18

#	ARTICLE	IF	CITATIONS
20	AB0667â€¦SPECIFICITY OF ANTI-TRNA SYNTHETASE AUTOANTIBODIES CORRELATED WITH CLINICAL COURSE AND PROGNOSIS OF MYOSITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE. , 2019, , .		0
21	AB0668â€¦ASSOCIATION OF ANTI-RNA POLYMERASE III ANTIBODY AND BREAST IMPLANTS RUPTURE IN ITALIAN PATIENTS WITH SYSTEMIC SCLEROSIS. , 2019, , .		1
22	AB0669â€¦THE EFFECTS OF BOSENTAN FOR TREATMENT OF DIGITAL ULCER IN KOREAN PATIENTS WITH SYSTEMIC SCLEROSIS: PROSPECTIVE, MULTICENTER, OPEN-LABEL TRIAL. , 2019, , .		0
23	Roles of aminoacyl-tRNA synthetases in immune regulation and immune diseases. <i>Cell Death and Disease</i> , 2019, 10, 901.	2.7	58
24	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. <i>Journal of Clinical Medicine</i> , 2019, 8, 2013.	1.0	118
25	Long-term pulmonary outcomes and mortality in idiopathic inflammatory myopathies associated with interstitial lung disease. <i>Clinical Rheumatology</i> , 2019, 38, 803-815.	1.0	27
26	A high level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis. <i>Clinical and Experimental Immunology</i> , 2020, 199, 314-325.	1.1	27
27	AsociaciÃ³n sÃ­ndrome antisintetasa y cÃ¡ncer. <i>Medicina ClÃ­nica</i> , 2020, 155, 130.	0.3	0
28	Association antisynthetase syndrome and cancer. <i>Medicina ClÃ­nica (English Edition)</i> , 2020, 155, 130.	0.1	0
29	Human diseases linked to cytoplasmic aminoacyl-tRNA synthetases. <i>The Enzymes</i> , 2020, 48, 277-319.	0.7	18
31	Anti-â€œlanyl tRNA positive antisynthase syndrome with Kaposi sarcoma. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 828-832.	0.9	1
32	Clinical features and outcomes of the patients with anti-glycyl tRNA synthetase syndrome. <i>Clinical Rheumatology</i> , 2020, 39, 2417-2424.	1.0	14
33	A prospective cross-sectional study of serum IL-17A in antisynthetase syndrome. <i>Clinical Rheumatology</i> , 2020, 39, 2763-2771.	1.0	11
34	Clinical characteristics of patients with anti-EJ antisynthetase syndrome associated interstitial lung disease and literature review. <i>Respiratory Medicine</i> , 2020, 165, 105920.	1.3	10
35	PL-7 Antisynthetase Syndrome in Association with SjÃ¶grenâ€™s, Systemic Lupus Erythematosus, and Rheumatoid Arthritis. <i>Case Reports in Rheumatology</i> , 2020, 2020, 1-4.	0.2	2
36	Antisynthetase syndrome: A distinct disease spectrum. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 178-191.	1.0	24
37	Clinical, radiological, and pathological features of anti-asparaginyl tRNA synthetase antibody-related interstitial lung disease. <i>Respiratory Investigation</i> , 2020, 58, 196-203.	0.9	9
38	Recognition and Management of Myositis-Associated Rapidly Progressive Interstitial Lung Disease. <i>Chest</i> , 2020, 158, 252-263.	0.4	40

#	ARTICLE	IF	CITATIONS
39	Increased serum soluble programmed death ligand 1 (sPD-L1) is associated with the presence of interstitial lung disease in rheumatoid arthritis: A monocentric cross-sectional study. <i>Respiratory Medicine</i> , 2020, 166, 105948.	1.3	13
40	Clinical manifestations and treatment of antisynthetase syndrome. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101503.	1.4	62
41	Predictive Features and Clinical Presentation of Interstitial Lung Disease in Inflammatory Myositis. <i>Clinical Reviews in Allergy and Immunology</i> , 2021, 60, 87-94.	2.9	24
42	The relationship between JAK2(V617F) mutation and dermatomyositis—a case report and literature review. <i>Clinical Rheumatology</i> , 2021, 40, 1147-1157.	1.0	3
43	Antisynthetase syndrome “much more than just a myopathy. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 72-83.	1.6	47
44	Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study. <i>Rheumatology</i> , 2021, 60, 1784-1792.	0.9	25
45	Prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease: a retrospective study of 679 adult cases. <i>Rheumatology</i> , 2021, 60, 1195-1204.	0.9	18
46	Baseline Characteristics and Survival of an Australian Interstitial Pneumonia with Autoimmune Features Cohort. <i>Respiration</i> , 2021, 100, 853-864.	1.2	10
47	Anti-synthetase syndrome: a rare and challenging diagnosis for bilateral ground-glass opacities—a case report with literature review. <i>BMC Pulmonary Medicine</i> , 2021, 21, 11.	0.8	13
48	Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China. <i>BMC Pulmonary Medicine</i> , 2021, 21, 57.	0.8	25
49	Clinical characteristics of Vietnamese patients with idiopathic inflammatory myopathies and autoantibodies to aminoacyl-tRNA synthetases. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 663-670.	0.9	2
50	Geographical Latitude Remains as an Important Factor for the Prevalence of Some Myositis Autoantibodies: A Systematic Review. <i>Frontiers in Immunology</i> , 2021, 12, 672008.	2.2	8
51	Rare presentation of antisynthetase syndrome complicated by myocarditis resulting in sustained ventricular tachycardia. <i>BMJ Case Reports</i> , 2021, 14, e234396.	0.2	0
52	Detección de autoanticuerpos en el lavado broncoalveolar en pacientes con enfermedad pulmonar intersticial difusa. <i>Archivos De Bronconeumología</i> , 2021, 57, 351-358.	0.4	1
53	Detection of autoantibodies in bronchoalveolar lavage in patients with diffuse interstitial lung disease. <i>Archivos De Bronconeumología</i> , 2021, 57, 351-358.	0.4	6
54	Clinical characteristics of interstitial lung diseases positive to different anti-synthetase antibodies. <i>Medicine (United States)</i> , 2021, 100, e25816.	0.4	12
55	Myositis specific antibodies are associated with isolated anti-Ro-52 associated interstitial lung disease. <i>Rheumatology</i> , 2022, 61, 1083-1091.	0.9	8
56	A 12-Year-Old Girl Presenting With Recurrent Dyspnea and Pulmonary Ground-Glass Opacities. <i>Chest</i> , 2021, 160, e45-e50.	0.4	1

#	ARTICLE	IF	CITATIONS
57	Manifestation of severe pneumonia in anti-PL-7 antisynthetase syndrome and B cell lymphoma: A case report. <i>World Journal of Clinical Cases</i> , 2021, 9, 6435-6442.	0.3	2
58	Anti Ro52 antibodies: One step further, but still not there yet. <i>European Journal of Internal Medicine</i> , 2021, 91, 31-32.	1.0	0
59	Clinical significance of anti-Ro52 (TRIM21) antibodies in adult patients with connective tissue diseases. <i>European Journal of Internal Medicine</i> , 2021, 91, 45-52.	1.0	10
60	Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110324.	1.2	30
61	Antisynthetase Syndrome and Autoantibodies: A Literature Review and Report of 4 Cases. <i>American Journal of Case Reports</i> , 2019, 20, 1094-1103.	0.3	8
62	Interstitial Lung Disease in Anti-Synthetase Syndrome. <i>Mediterranean Journal of Rheumatology</i> , 2019, 30, 186.	0.3	2
63	Soluble programmed death molecule 1 (sPD-1) as a predictor of interstitial lung disease in rheumatoid arthritis. <i>BMC Immunology</i> , 2021, 22, 69.	0.9	5
64	Interstitial pneumonia associated with autoimmune diseases: a possible mimicker of SARS-CoV-2 pneumonia. <i>Internal and Emergency Medicine</i> , 2022, 17, 577-581.	1.0	1
65	Hyperkeratotic fissured plaques on both hands: Mechanicâ€™s hands. <i>Cleveland Clinic Journal of Medicine</i> , 2018, 85, 268-269.	0.6	1
66	Traditional Myositis Autoantibodies: Synthetase, Mi-2, SRP, Ku, PM-Scl, Ro, U1RNP. , 2020, , 181-192.		0
67	Clinical profile and treatment outcomes in antisynthetase syndrome: a tertiary centre experience. <i>Rheumatology Advances in Practice</i> , 2021, 5, ii10-ii18.	0.3	1
69	Interstitial lung disease is not rare in immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies. <i>BMC Pulmonary Medicine</i> , 2022, 22, 14.	0.8	9
70	An updated review of anti-Ro52 (TRIM21) antibodies impact in connective tissue diseases clinical management. <i>Autoimmunity Reviews</i> , 2022, 21, 103013.	2.5	15
71	Anti-Ro52 Autoantibody Is Common in Systemic Autoimmune Rheumatic Diseases and Correlating with Worse Outcome when Associated with interstitial lung disease in Systemic Sclerosis and Autoimmune Myositis. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 63, 178-193.	2.9	18
72	Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease. <i>Rheumatology</i> , 2022, 61, 4570-4578.	0.9	29
73	A case of Fulminant Respiratory Failure Caused by Anti-asparaginyl tRNA Synthetase (Anti-KS) Antibody Syndrome-related Interstitial Lung Disease. <i>Internal Medicine</i> , 2022, , .	0.3	1
74	Inflammatory myopathy, mixed connective tissue disease, and antisynthetase syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2022, , 105-151.	0.1	0
75	Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome. <i>Frontiers in Immunology</i> , 2022, 13, 845988.	2.2	23

#	ARTICLE	IF	CITATIONS
76	Demographic, clinical, laboratory data, prognostic, and treatment features of patients with antisynthetase syndrome: An international, two-center cohort study. <i>Archives of Rheumatology</i> , 2022, 37, 424-434.	0.3	1
77	Anti- α 1 autoantibodies, from clinic to the bench. <i>Rheumatology & Autoimmunity</i> , 2022, 2, 57-68.	0.3	5
78	Antisynthetase syndrome sine myositis presenting as severe acute respiratory failure. <i>BMJ Case Reports</i> , 2022, 15, e248358.	0.2	0
79	Myositis-specific antibodies: Overview and clinical utilization. <i>Rheumatology and Immunology Research</i> , 2022, 3, 1-10.	0.2	11
80	Overlap between Sjogren's syndrome and anti-synthetase syndrome: association or coincidence?. <i>Archives of Medical Science</i> , 2022, 18, 820-821.	0.4	0
81	Interstitial Lung Disease in Dermatomyositis Without Myositis-Specific and Myositis-Associated Autoantibodies: Study of a Series of 72 Patients From a Single Cohort. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	5
82	Aminoacyl-tRNA Synthetases: On Anti-Synthetase Syndrome and Beyond. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	27
83	256th ENMC international workshop: Myositis specific and associated autoantibodies (MSA-ab): Amsterdam, The Netherlands, 8-10 October 2021. <i>Neuromuscular Disorders</i> , 2022, 32, 594-608.	0.3	13
84	A Rare Case of Anti-glycyl transfer RNA (tRNA) Synthetase Antibody-Related Non-specific Interstitial Pneumonia. <i>Cureus</i> , 2022, , .	0.2	1
85	Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies: results from a cohort from China. <i>Clinical Rheumatology</i> , 2022, 41, 3419-3427.	1.0	5
86	Clinical features, prognostic factors, and survival of patients with antisynthetase syndrome and interstitial lung disease. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
88	The Role of Myositis-Specific Autoantibodies and the Management of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: A Systematic Review. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 57, 152088.	1.6	8
89	A prognostic analysis of antisynthetase syndrome-related interstitial lung disease. <i>International Journal of Rheumatic Diseases</i> , 2022, 25, 1368-1375.	0.9	3
90	Risk Factors and Predictive Model for Dermatomyositis Associated with Rapidly Progressive Interstitial Lung Disease. <i>Pharmacogenomics and Personalized Medicine</i> , 0, Volume 15, 775-783.	0.4	0
91	Analysis of the clinical features of antisynthetase syndrome: a retrospective cohort study in China. <i>Clinical Rheumatology</i> , 2023, 42, 703-709.	1.0	4
92	Ro52, Myositis, and Interstitial Lung Disease. <i>Journal of Rheumatology</i> , 2023, 50, 161-163.	1.0	7
93	An observational study of clinical recurrence in patients with interstitial lung disease related to the antisynthetase syndrome. <i>Clinical Rheumatology</i> , 0, , .	1.0	1
94	A rare presentation of antisynthetase syndrome requiring intensive care in the midst of a COVID wave. <i>Modern Rheumatology Case Reports</i> , 2023, 7, 394-398.	0.3	0

#	ARTICLE	IF	CITATIONS
95	Clinical features and outcomes of patients with myositis associated-interstitial lung disease. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	6
96	Clinical Characteristics and Associated Factors for Infection and in-Hospital Mortality in Inpatients with Polymyositis/Dermatomyositis in China: A Retrospective Study. <i>Infection and Drug Resistance</i> , 0, Volume 16, 289-299.	1.1	2
97	Inflammatory myositis-associated interstitial lung disease can be distinguished from that associated with other connective tissue diseases. <i>Journal of Thoracic Disease</i> , 2023, 15, 311-322.	0.6	2
98	Recurrent Exacerbations and Evolution into Polymyositis in a Patient with Interstitial Pneumonia with Autoimmune Features: A Case Report and Literature Review. <i>Medicina (Lithuania)</i> , 2023, 59, 330.	0.8	1
99	Clinical Outcomes With and Without Plasma Exchange in the Treatment of Rapidly Progressive Interstitial Lung Disease Associated With Idiopathic Inflammatory Myopathy. <i>Journal of Clinical Rheumatology</i> , 2023, 29, 151-158.	0.5	1
100	Diagnosis and Management of Myositis-Associated Lung Disease. <i>Chest</i> , 2023, 163, 1476-1491.	0.4	10
101	Rituximab as the first-line therapy in anti-synthetase syndrome-related interstitial lung disease. <i>Rheumatology International</i> , 0, , .	1.5	1
102	Overlap syndrome with antibodies against multiple transfer-RNA components presenting antisynthetase syndrome. <i>Neuromuscular Disorders</i> , 2023, 33, 405-409.	0.3	0
103	Predictive factors for progressive fibrosing interstitial lung disease in anti-synthetase syndrome. <i>International Journal of Rheumatic Diseases</i> , 2023, 26, 885-894.	0.9	2
104	Clinical Characterization and Predictive Factors for Progression in a Cohort of Patients with Interstitial Lung Disease and Features of Autoimmunity: The Need for a Revision of IPAF Classification Criteria. <i>Medicina (Lithuania)</i> , 2023, 59, 794.	0.8	1
109	Anti-synthetase syndrome and the risk of progressive pulmonary fibrosis: weighting of concomitant anti-Ro/SSA antibodies. <i>Clinical Rheumatology</i> , 2023, 42, 2249-2250.	1.0	0